FEMY FEMASYS INC

Nasdaq femasys.com


$ 0.74 $ -0.08 (-9.58 %)    

Tuesday, 18-Nov-2025 15:58:03 EST
QQQ $ 597.12 $ -7.35 (-1.22 %)
DIA $ 461.67 $ -5.02 (-1.08 %)
SPY $ 660.81 $ -5.59 (-0.84 %)
TLT $ 89.05 $ -0.03 (-0.03 %)
GLD $ 374.31 $ 2.70 (0.73 %)
$ 0.72
$ 0.78
$ 0.73 x 5
$ 0.74 x 100
$ 0.70 - $ 0.80
$ 0.31 - $ 1.80
2,676,848
na
nm
$ 0.38
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-14-2025 09-30-2025 10-Q
2 08-08-2025 06-30-2025 10-Q
3 05-08-2025 03-31-2025 10-Q
4 03-27-2025 12-31-2024 10-K
5 11-12-2024 09-30-2024 10-Q
6 08-08-2024 06-30-2024 10-Q
7 05-09-2024 03-31-2024 10-Q
8 03-28-2024 12-31-2023 10-K
9 11-14-2023 09-30-2023 10-Q
10 08-10-2023 06-30-2023 10-Q
11 05-11-2023 03-31-2023 10-Q
12 03-30-2023 12-31-2022 10-K
13 11-10-2022 09-30-2022 10-Q
14 08-10-2022 06-30-2022 10-Q
15 05-11-2022 03-31-2022 10-Q
16 03-24-2022 12-31-2021 10-K
17 11-12-2021 09-30-2021 10-Q
18 08-11-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 femasys-q3-eps-010-beats-012-estimate-sales-729394k-miss-1450m-estimate

Femasys (NASDAQ:FEMY) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.12) by 13...

 femasys-announces-start-of-post-market-surveillance-clinical-study-for-its-ce-marked-fembloc-permanent-birth-control-conducted-under-eu-medical-device-regulation-in-collaboration-with-regional-medical-experts

Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more acces...

Core News & Articles

- Reuters

Core News & Articles

https://www.youtube.com/watch?v=xagrobF4q1k 

Core News & Articles

https://www.youtube.com/watch?v=xagrobF4q1k 

Core News & Articles

https://www.nytimes.com/2025/10/16/us/politics/trump-ivf-fertility.html

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION